Johnson & Johnson has completed the acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company developing oral, targeted therapies for solid tumours using its proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC) platform. The transaction was completed for USD 3.05 billion in cash.

The acquisition reinforces Johnson & Johnson’s strategy to advance breakthrough oncology innovation. Halda brings to the company a differentiated RIPTAC technology designed to selectively target and eliminate cancer cells, with potential applications across multiple solid tumour indications, including prostate cancer.

“With this strategic milestone, we are reinforcing our commitment to transforming cancer care through cutting-edge science and innovative medicines,” said Jennifer Taubert, executive vice president and worldwide chairman, Innovative Medicine, Johnson & Johnson. She added that the company looks forward to integrating Halda’s team and capabilities to advance the shared goal of eliminating cancer.

As part of the deal, Johnson & Johnson adds HLD-0915, a clinical-stage, once-daily oral therapy for prostate cancer, to its oncology portfolio. The candidate leverages the RIPTAC platform to address treatment resistance through a precision cancer cell-targeting mechanism. In addition, the acquisition includes several earlier-stage programmes targeting breast cancer, lung cancer, and other solid tumours, expanding Johnson & Johnson’s oncology pipeline. The RIPTAC technology also holds potential for applications beyond oncology.

John C. Reed, executive vice president, Innovative Medicine, R&D, Johnson & Johnson, said the company will now focus on accelerating development of Halda’s pipeline while using the RIPTAC platform to discover additional novel therapeutic.